Collectively, we find that rrDLBCL tumors are prone to DNA losses, gains, and rearrangements that result in amplification of lymphoma driver genes (e.g., MYC, BCL2, IL10) or depletion of critical tumor suppressor genes (e.g., TOP3A, CD70, TP53). The gene discussed is BCL2; the disease is lymphoma.